Profound Medical (PROF)
(Delayed Data from NSDQ)
$4.34 USD
+0.21 (5.08%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $4.38 +0.04 (0.92%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PROF 4.34 +0.21(5.08%)
Will PROF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROF
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Other News for PROF
PROF forms Pocket Pivot on September 19
The technical outlook for PROF is unchanged after it falls 1.78% on September 17
MACD Bullish Signal Line Cross appears for PROF after 1.22% move
Is PROF primed for downward momentum? 1,2,3 Retracement Bearish shows up after rising 1.24%
NR7 appears for PROF after 2.02% move